IQVIA (France)

本机构学者在这里署名、按本站篇数

合作机构同一篇文章里的其他机构

1. Teva Pharmaceuticals (Israel)以色列6
2. Sanofi (France)法国5
3. Utrecht University荷兰2
4. Sanofi (Canada)加拿大2
5. Vifor Pharma (Switzerland)瑞士2
6. IQVIA (Portugal)葡萄牙2
7. London School of Hygiene & Tropical Medicine英国1
8. Gedeon Richter (Hungary)匈牙利1

按月发文

逐年被引

最新文献

1. 1
   Assessing the Risk of Adverse Maternal and Infant Outcomes Following Prenatal Modafinil Exposure: A French Nationwide Cohort StudyDrug Safety20260
2. 2
   Successful Linkage of Electronic Medical Records and National Health Data System in Type 2 Diabetes Research: Methodological Insights and ImplicationsPharmacoepidemiology and Drug Safety20250
3. 3
   Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European CountriesPharmacoepidemiology and Drug Safety20243
4. 4
   Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping reviewPharmacoepidemiology and Drug Safety202423
5. 5
   Impact of European Union label changes to avoid inadvertent use of medicinal products containing methotrexate for once‐weekly administration: A survey amongst prescribers, pharmacists and patients on awareness, knowledge, and behaviourPharmacoepidemiology and Drug Safety20233
6. 6
   A drug utilization study of thiocolchicoside‐containing medicinal products for systemic use in France and Italy: A cross‐sectional electronic medical records database studyPharmacoepidemiology and Drug Safety20233
7. 7
   HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real‐world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task forcePharmacoepidemiology and Drug Safety2022114
8. 8
   A cross‐sectional survey to evaluate prescribers' knowledge and understanding of safety messages following Dengvaxia ® product information updatePharmacoepidemiology and Drug Safety20223
9. 9
   A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in EuropePharmacoepidemiology and Drug Safety202113
10. 10
    Effectiveness of risk minimisation measures for valproate: A cross‐sectional survey among physicians in EuropePharmacoepidemiology and Drug Safety202010

高被引文献

1. 1
   HARmonized Protocol Template to Enhance Reproducibility of hypothesis evaluating real‐world evidence studies on treatment effects: A good practices report of a joint ISPE/ISPOR task forcePharmacoepidemiology and Drug Safety2022114
2. 2
   Evaluation of the Reported Rates of Severe Hypersensitivity Reactions Associated with Ferric Carboxymaltose and Iron (III) Isomaltoside 1000 in Europe Based on Data from EudraVigilance and VigiBase™ between 2014 and 2017Drug Safety201835
3. 3
   Describing diversity of real world data sources in pharmacoepidemiologic studies: The DIVERSE scoping reviewPharmacoepidemiology and Drug Safety202423
4. 4
   Effectiveness of risk minimisation measures for valproate: A drug utilisation study in EuropePharmacoepidemiology and Drug Safety202020
5. 5
   A review of the sampling methodology used in studies evaluating the effectiveness of risk minimisation measures in EuropePharmacoepidemiology and Drug Safety202113
6. 6
   Effectiveness of risk minimisation measures for valproate: A cross‐sectional survey among physicians in EuropePharmacoepidemiology and Drug Safety202010
7. 7
   Evaluation of the effectiveness of risk minimization measures for trimetazidine: A cross sectional joint PASS survey among physicians in selected European countriesPharmacoepidemiology and Drug Safety20188
8. 8
   A cross‐sectional survey to evaluate prescribers' knowledge and understanding of safety messages following Dengvaxia ® product information updatePharmacoepidemiology and Drug Safety20223
9. 9
   Impact of European Union label changes to avoid inadvertent use of medicinal products containing methotrexate for once‐weekly administration: A survey amongst prescribers, pharmacists and patients on awareness, knowledge, and behaviourPharmacoepidemiology and Drug Safety20233
10. 10
    Effectiveness of the Additional Risk Minimisation Measures for Valproate Among Healthcare Professionals and Patients: A Cross‐Sectional Survey in Six European CountriesPharmacoepidemiology and Drug Safety20243

主要发表期刊

研究主题